Competitive LandscapeApril 2026
Sanofi Trims Nanobody Programs: Target Selection Matters More Than Platform
Sanofi (which acquired Ablynx for 3.9B EUR) trims two nanobody programs (anti-CX3CR1 for inflammation, GPC3 nanobody T-cell engager for solid tumors) while advancing multi-targeting designs with up to 7 nanobody subunits. The platform now has ~40 programs with 4 in clinical development.
JFInnova Perspective
Even with a $4B platform, picking the right target is critical — Sanofi's cancelled programs prove it. JFInnova chose the MIF/CD74 axis based on rigorous single-cell transcriptomics analysis and digital twin validation, not intuition. The same week Sanofi cuts programs, Nature Neuroscience and Cancer Research publish direct validations of our target.
References
1
Sanofi cuts programs tied to multi-billion-dollar deals
Fierce Biotech · 2026
Sanofi Ablynx nanobody target selection pipeline